ASK THE DOCTOR: Will this new drug stop me losing my sight?
Dr Martin Scurr advises a patient who has been treated with Lucentis for an eye condition for years. She has now been prescribed Eylea. (Source: the Mail online | Health)
Source: the Mail online | Health - April 22, 2014 Category: Consumer Health News Source Type: news
Cost of Treatment May Influence Doctors
The American College of Cardiology and the American Heart Association said they would use cost data to rate the value of treatments. (Source: NYT)
Source: NYT - April 18, 2014 Category: American Health Authors: By ANDREW POLLACK Tags: Lucentis (Drug) Gilead Sciences Inc GILD NASDAQ JPMorgan Chase & Company JPM NYSE Drugs (Pharmaceuticals) American Heart Assn American Society of Clinical Oncology Health Insurance and Managed Care Avastin (Drug) American College of Ca Source Type: news
Ranibizumab Holds Visual Line in Real-World StudyRanibizumab Holds Visual Line in Real-World Study
A postmarketing study shows that previously treated and treatment-naïve patients had good visual acuity results at 1 year, with a low incidence of adverse ocular events. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 16, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Visual Outcomes in DME Treated With RanibizumabVisual Outcomes in DME Treated With Ranibizumab
Why do some DME patients continue to have poor vision after ranibizumab therapy? This new study examines the issue. Eye (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 9, 2014 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Novartis introduces Lucentis® in state of the art pre-filled syringe
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which received European approval in October 2013, is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 24, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Ophthalmology Latest News Source Type: news
Novartis Launches Lucentis In Intraocular Injection
Novartis announced it is launching Lucentis (ranibizumab) in pre-filled syringe (PFS) formulation designed for intraocular injection in Germany. The product will be launched in other markets throughout this year. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 21, 2014 Category: Pharmaceuticals Source Type: news
Ranibizumab Treatment for Neovascular AMDRanibizumab Treatment for Neovascular AMD
Are there risk factors for being a 'reduced responder' to ranibizumab treatment for AMD, and if so, what should clinicians be aware of? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 26, 2014 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Japanese authorities approve fourth indication for Genentech-Novartis' eye drug Lucentis
The Japanese regulatory bodies have approved Lucentis (ranibizumab) for a fourth indication for treatment of patients with diabetic macular edema (DME), a major cause of vision loss among diabetic patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 25, 2014 Category: Pharmaceuticals Source Type: news
Ranibizumab and Long-Term Diabetic Macular Edema OutcomesRanibizumab and Long-Term Diabetic Macular Edema Outcomes
The benefits of individualized ranibizumab treatment for diabetic macular edema (DME) persist for at least three years, according to results from the RESTORE extension study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 17, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Bevacizumab vs Ranibizumab: Cost-Effectiveness for AMDBevacizumab vs Ranibizumab: Cost-Effectiveness for AMD
Bevacizumab is more cost-effective than ranibizumab for the treatment of newly diagnosed neovascular macular degeneration, according to a mathematical model. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 14, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Developments in the treatment of AMD
Eylea (aflibercept) is a new anti-vascular endothelial growth growth factor inhibitor that is as effective and safe as ranibizumab in the treatment of neovascular age-related macular degeneration (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 14, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Aerpio doses first patient in Phase II trial of diabetic macular edema drug AKB-9778
US-based clinical-stage biopharmaceutical firm Aerpio Therapeutics has dosed the first patient in a Phase II trial designed to evaluate AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for treatment of diabetic macular… (Source: Drug Development Technology)
Source: Drug Development Technology - February 14, 2014 Category: Pharmaceuticals Source Type: news
Roche delivers strong 2013 results
Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics sales up 4% on strong Professional Diagnostics performance (Source: Roche Investor Update)
Source: Roche Investor Update - January 30, 2014 Category: Pharmaceuticals Source Type: news
AMD: Gene Variants Predict Response to Anti-VEGF DrugAMD: Gene Variants Predict Response to Anti-VEGF Drug
Minor alleles of the vascular endothelial growth factor 2 receptor gene predict response to ranibizumab treatment for wet AMD. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab for AMD: Dose and FrequencyRanibizumab for AMD: Dose and Frequency
The HARBOR study compared the efficacy and safety of 2 doses and 2 injection frequencies in patients with age-related macular degeneration. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2013 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
